Prescription drug negotiation provisions under the Inflation Reduction Act will lower prices on high-cost drugs for the Medicare population, but will it lead to higher or lower expenses on the commercial market? Time will tell, according to Jeff Levin-Scherz, assistant professor at the Harvard T.H. Chan School of Public Health, and Population Health Leader in the Health Management Practice at WTW. Levin-Scherz joins Bloomberg Intelligence Analyst Duane Wright on this episode of the Votes and Verdicts podcast to discuss the potential spillover effects of Medicare drug prices for employers. He also shares his views on other policies that can be implemented to drive down drug prices. 

See omnystudio.com/listener for privacy information.